Perceptive Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $35.5 Million - $41.1 Million	-409,853 Reduced 60.89%	263,207 $22.8 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $14.6 Million - $19.5 Million	166,579 Added 32.89%	673,060 $65.4 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $13.8 Million - $18.5 Million	170,000 Added 50.52%	506,481 $52.4 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $12.9 Million - $15.2 Million	156,481 Added 86.93%	336,481 $28.5 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $12.9 Million - $15.6 Million	180,000 New	180,000 $14.9 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $87.7 Million - $109 Million	-1,180,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $84.6 Million - $108 Million	1,180,000 New	1,180,000 $104 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.